Elsevier

Clinical Therapeutics

Volume 25, Issue 8, August 2003, Pages 2155-2181
Clinical Therapeutics

New drug
The role of clopidogrel in the management of acute coronary syndromes

https://doi.org/10.1016/S0149-2918(03)80211-4Get rights and content

Abstract

Background: Despite significant advances in the management of coronary heart disease, myocardial infarction (MI) is still associated with a mortality rate of 45%. Acetylsalicylic acid (ASA) has been the oral antiplatelet drug of choice until recently. Thienopyridines such as clopidogrel have been shown to provide significant benefits in the management of acute coronary syndromes (ACS), either as an alternative to or in combination with ASA therapy.

Objective: The purpose of this article was to review the available scientific literature evaluating the use of clopidogrel in the management of ACS.

Methods: Relevant published data were identified through searches of the English-language literature indexed on MEDLINE and International Pharmaceutical Abstracts through April 2003. Search terms included thienopyridines, platelet aggregation inhibitors, clopidogrel, ticlopidine, acute coronary syndrome, myocardial infarction, and percutaneous coronary intervention. Pertinent conference abstracts were also included.

Results: The results of 3 large clinical trials-Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE), Effect of Pretreatment with Clopidogrel and Aspirin Followed by Long-Term Therapy in Patients Undergoing Percutaneous Coronary Intervention (PCI-CURE), and Clopidogrel for the Reduction of Events During Observation (CREDO)-support prolonged use of clopidogrel (up to 12 months) in combination with ASA in patients with non-ST-segment elevation MI and patients undergoing a percutaneous coronary intervention (PCI). A significant increase in bleeding events was observed in the group that received clopidogrel plus ASA compared with ASA alone in the CURE (major bleeding, P = 0.001; minor bleeding, P < 0.001) and PCI-CURE (minor bleeding, P = 0.03) trials. Use of the combination of clopidogrel and ASA with other antiplatelet and/or anticoagulant agents has not been studied extensively.

Conclusions: Use of the combination of clopidogrel and ASA for up to 9 months is recommended for the medical management of non-ST-segment elevation MI and after a PCI. The increased risk of bleeding must be taken into account, and use of this combination with other agents that affect bleeding risk should be considered carefully.

References (83)

  • G.J. Mishkel et al.

    Clopidogrel as adjunctive antiplatelet therapy during coronary stenting

    J Am Coll Cardiol

    (1999)
  • R. Jauhar et al.

    Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting

    Am J Cardiol

    (1999)
  • S.R. Mehta et al.

    Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study

    Lancet

    (2001)
  • R. Hongo et al.

    The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting

    J Am Coll Cardiol

    (2002)
  • G.J. Hankey

    Clopidogrel and thrombotic thrombocytopenic purpura

    Lancet

    (2000)
  • J.M. Trivier et al.

    Fatal aplastic anaemia associated with clopidogrel

    Lancet

    (2001)
  • B. Meyer et al.

    Clopidogrel and aplastic anaemia

    Lancet

    (2001)
  • V.L. Serebruany et al.

    Statins do not affect platelet inhibition with clopidogrel during coronary stenting

    Atherosclerosis

    (2001)
  • Y. Yeghiazarians et al.

    Unstable angina pectoris

    N Engl J Med

    (2000)
  • H.C. Stary et al.

    A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association

    Circulation

    (1995)
  • M.J. Davies

    The pathophysiology of acute coronary syndromes

    Heart

    (2000)
  • R. Virmani et al.

    Vulnerable plaque: The pathology of unstable coronary lesions

    J Intervent Cardiol

    (2002)
  • R. Corti et al.

    Biologic aspects of vulnerable plaque

    Curr Opin Cardiol

    (2002)
  • R.C. Becker et al.

    Pathobiology of thrombin in acute coronary syndromes

    Am Heart J

    (1998)
  • E. Braunwald et al.

    ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—summary article: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina)

    J Am Coll Cardiol

    (2002)
  • T.J. Ryan et al.

    1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)

    Circulation

    (1999)
  • Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2

    Lancet

    (1988)
  • Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

    BMJ

    (2002)
  • J.A. Cairns et al.

    Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial

    N Engl J Med

    (1985)
  • H.D. Lewis et al.

    Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study

    N Engl J Med

    (1983)
  • P. Theroux et al.

    Aspirin, heparin, or both to treat acute unstable angina

    N Engl J Med

    (1988)
  • The EPIC Investigation

    Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

    N Engl J Med

    (1994)
  • The CAPTURE Investigators

    Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study

    Lancet

    (1997)
  • The EPILOG Investigators

    Platelet glycoprotein IIb/IIIa receptor blockade and lowdose heparin during percutaneous coronary revascularization

    N Engl J Med

    (1997)
  • The EPISTENT Investigators

    Randomised placebo-controlled and balloon-angioplastycontrolled trial to assess safety of coronary stenting with use of platelet glycoproteinIIb/IIIa blockade

    Lancet

    (1998)
  • Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators

    A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

    N Engl J Med

    (1998)
  • Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators

    Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Qwave myocardial infarction

    N Engl J Med

    (1998)
  • The PURSUIT Trial Investigators

    Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy

    N Engl J Med

    (1998)
  • J.C. O'Shea et al.

    Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT trial: A randomized controlled trial

    JAMA

    (2001)
  • D.P. Chew et al.

    Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A meta-analysis of phase III multicenter randomized trials

    Circulation

    (2001)
  • Cited by (0)

    View full text